FDA warns on risk of HBV reactivation in patients taking direct-acting antivirals for HCV Oct. 6, 2016
Mitsubishi Tanabe and Daiichi Sankyo announce progress in malaria research programs with MMV Oct. 6, 2016
Contract between BARDA and Emergent Biosolutions will support advancement of anthrax vaccine Oct. 4, 2016
Glecaprevir/pibrentasvir investigational HCV regimen receives FDA breakthrough therapy designation Oct. 3, 2016
RSS